Trial Profile

A Phase I/II, first-in-human, single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of HMB-001 in participants With Glanzmann thrombasthenia

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Mar 2026 According to a Hemab media release, based positive results from the completed Phase 2 multiple ascending dose portion the U.S. FDA has granted Breakthrough Therapy Designation (BTD) for sutacimig for the prevention of bleeding episodes in patients with Glanzmann thrombasthenia (GT).
08 Dec 2025 According to a Hemab media release, data from this study was presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando
08 Dec 2025 Results presented in the Hemab Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com